Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 12 Small Cap Stocks with High Upside Potential. On June 4, the company published pre-specified analyses for its vadadustat global phase 3 clinical program. The program consisted of two trials for patients with dialysis-dependent chronic kidney disease and two trials for patients with non-dialysis-dependent chronic kidney disease.

The pre-specified analyses revealed that patients with DD-CKD reported similar efficacy and safety levels for vadadustat and darbepoetin alfa in both the United States and outside the United States.

Vafseo referred to as vadadustat, was originally approved by the US Food and Drug Administration last year in March to treat anaemia due to chronic kidney disease. The drug has been available in the United States since January 2025.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on improving the lives of people with kidney disease. The company has two drugs approved by the FDA.

While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.